Physician profile
Peter J Charap
NPI 1407962509
$7,884.12
in general payments reported to CMS, 2019-2025
29 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,717 · 2020: $1,597 · 2021: $85.36 · 2022: $599 · 2023: $1,431 · 2024: $1,231 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,886.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $980.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $767.43 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $659.63 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Lundbeck LLC | $617.84 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $615.63 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $574.23 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Gilead Sciences, INC. | $537.34 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $514.86 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $486.84 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $448.78 | 2019-2020 | |
| Exact Sciences Corporation | $437.23 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $230.55 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $171.18 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $162.72 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $155.76 | 2024-2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $144.20 | 2019-2023 | Veozah |
| Otsuka America Pharmaceutical, INC. | $77.80 | 2023-2025 | Rexulti |
| Mission Pharmacal Company | $45.15 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.18 | 2025 | Caplyta |
| Amgen INC. | $37.81 | 2020 | |
| Bausch Health US, LLC | $25.00 | 2024 | Wellbutrin, Aplenzin |
| Janssen Pharmaceuticals, INC | $25.00 | 2020 | |
| Esperion Therapeutics, INC. | $22.54 | 2025 | Nexletol |
| Genentech USA, INC. | $19.62 | 2019 | |
| Shire North American Group INC | $18.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.07 | 2023 | |
| Sanofi Pasteur INC. | $17.61 | 2019 | |
| Kyowa Kirin, INC. | $15.64 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Charap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.